| Literature DB >> 25405163 |
Ali Hasan Ebrahim1, Zainab Alalawi1, Leonardo Mirandola1, Rahman Rakhshanda1, Scott Dahlbeck1, Diane Nguyen1, Marjorie Jenkins1, Fabio Grizzi1, Everardo Cobos1, Jose A Figueroa1, Maurizio Chiriva-Internati1.
Abstract
A major breakthrough in the field of medical oncology has been the discovery of galectins and their role in cancer development, progression and metastasis. In this review article we have condensed the results of a number of studies published over the past decade in an effort to shed some light on the unique role played by the galectin family of proteins in neoplasia, and how this knowledge may alter the approach to cancer diagnosis as well as therapy in the future. In this review we have also emphasized the potential use of galectin inhibitors or modulators in the treatment of cancer and how this novel treatment modality may affect patient outcomes in the future. Based on current pre-clinical models we believe the use of galectin inhibitors/modulators will play a significant role in cancer treatment in the future. Early clinical studies are underway to evaluate the utility of these promising agents in cancer patients.Entities:
Keywords: Cancer; galectins; lectins; solid tumors
Year: 2014 PMID: 25405163 PMCID: PMC4205868 DOI: 10.3978/j.issn.2305-5839.2014.09.12
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839